ARPA-H Launches AEGIS Project: Affordable Gene-Editing Therapies for Pediatric Immune Diseases via CRISPR and LNP Delivery

Princeton University USA

Overview

The ARPA-H THRIVE-funded AEGIS project is pioneering the development of affordable gene-editing therapies for children suffering from rare inborn errors of immunity (IEIs). By leveraging advanced CRISPR base and prime editing technologies, efficiently delivered to bone marrow cells via lipid nanoparticles (LNPs), AEGIS aims to directly correct disease-causing mutations. This collaborative effort, involving leading research institutions, is designed to overcome the prohibitive costs of current gene therapies while ensuring robust safety and efficacy.

In Depth

Key Findings: ARPA-H-Backed AEGIS Project Pioneers Affordable CRISPR Gene Therapies for Pediatric Immune Disorders

The innovative collaborative research project known as “AEGIS (Affordable Gene Editing Therapies for Immune System Diseases of Children),” funded by the ARPA-H (Advanced Research Projects Agency for Health) THRIVE program, has commenced with the ambitious goal of developing affordable gene-editing therapies for pediatric patients afflicted with rare inborn errors of immunity (IEIs). This project harnesses highly precise base editing and prime editing, state-of-the-art CRISPR gene-editing technologies, to directly correct the underlying disease-causing genetic mutations. Addressing the significant challenge of high gene therapy costs that currently limit patient access, AEGIS aims to drastically reduce treatment expenses while simultaneously ensuring both safety and efficacy, primarily through the efficient delivery of gene-editing tools to bone marrow cells using advanced lipid nanoparticle (LNP) technology.

Technical and Clinical Details: Synergistic Effects of LNP Delivery and CRISPR Editing

• CRISPR Base Editing and Prime Editing: Base editing, a sophisticated technology, directly converts a single DNA base (e.g., A to G, C to T) without inducing double-strand breaks in the DNA, thereby significantly reducing the risk of off-target effects. Prime editing extends these capabilities, enabling even more complex genetic modifications, such as precise DNA segment insertions or targeted substitutions. The AEGIS project will strategically employ these cutting-edge CRISPR technologies to accurately correct the specific mutations responsible for IEIs.
• Optimization of LNP Delivery Technology: A critical hurdle in in vivo gene therapy is the safe and efficient delivery of gene-editing tools to the intended target cells. Lipid nanoparticles (LNPs) represent a proven delivery system, having demonstrated their efficacy in mRNA vaccines. This project will undertake intensive research to maximize LNP delivery efficiency, with a particular focus on targeting bone marrow cells. This innovation opens the promising possibility of directly editing hematopoietic stem cells within the patient’s body, offering a transformative approach to treating these diseases.
• Application to Pediatric Patients and Addressing Cost Challenges: Inborn errors of immunity often manifest shortly after birth and can lead to severe, life-threatening complications, making early intervention during childhood critically important. However, existing gene therapies have been plagued by exorbitant costs, frequently ranging from millions to hundreds of millions of dollars, creating substantial barriers to access. The AEGIS project seeks to render treatment affordable through optimized LNP delivery methods and streamlined manufacturing processes, anticipating benefits for a much larger population of pediatric patients.

Background and Industry Context: Impact on Rare Disease Treatment and Public Health

Rare immune diseases, characterized by their complex genetic underpinnings and diverse symptomatic presentations, represent a significant unmet need in both diagnosis and treatment. The ARPA-H THRIVE program is specifically designed to support such high-risk, high-reward medical research endeavors, aiming to tackle substantial public health challenges. This interdisciplinary collaboration, spearheaded by Princeton University and integrating expertise from the University of Utah, the University of California, San Diego, and Georgia Tech and Emory School of Medicine, coalesces cutting-edge academic knowledge to accelerate the translational pathway and commercialization of gene therapies.

Future Outlook: Transition to Clinical Trials and Global Impact

The immediate next step for the AEGIS project involves establishing robust preclinical data on the safety and efficacy of the developed LNP delivery system and gene-editing approaches in vivo. Successful completion of this phase will pave the way for a planned transition to human clinical trials, specifically targeting pediatric IEI patients. Crucial future work will include comparative evaluations of base editing versus prime editing approaches, detailed analysis of off-target effects, and comprehensive validation of long-term therapeutic efficacy. Should this groundbreaking project succeed, it could serve as a paradigm for overcoming both cost and accessibility challenges in gene-editing therapies for rare diseases, ultimately bringing profound hope to patients suffering from similar conditions worldwide.

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

• Your email and selected fields are used only to deliver the newsletter.
• We never share your information with third parties.
• You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Agree & Continue ▶

Takes about a minute · Unsubscribe anytime